Search

Search Results

• 

  Persistence of functional anti-PF4 antibodies and neutrophil activation in vaccine-induced immune thrombotic thrombocytopenia

  Eleonora Petito, Anna Maria Mezzasoma, Emanuela Falcinelli, Chiara Conti, Erica De Candia, Raimondo De Cristofaro, Silvia Sorrentino, Gian Marco Podda, Mariangela Scavone, Anna Falanga, Marina Marchetti, Luca Barcella, Stefania Basili, Lucia Stefanini, Andrea Boccatonda, Laura Contino, Patrizia Sciancalepore, Igor Florio, Egidio Imbalzano, Rossella Marcucci, Angela Rogolino, Patrizia Noris, Marta Panella, Rita Santoro, Maria Costanza Turi, Gaetano Vaudo, Rosa Curcio, Paolo Gresele

  18-11-2025

  https://doi.org/10.4081/btvb.2025.400

  624

  PDF: 101

  HTML: 61
• 

  Preface to the 13^th International Conference on Thrombosis and Hemostasis Issues in Cancer, 2026

  Anna Falanga, Benjamin Brenner, Alok A. Khorana

  16-04-2026

  https://doi.org/10.4081/btvb.2026.479

  0

  PDF: 0
• 

  The therapeutic landscape of cancer-associated splanchnic vein thrombosis

  Alessia Abenante, Filippo Catalani, Walter Ageno

  16-04-2026

  https://doi.org/10.4081/btvb.2026.458

  0

  PDF: 0

• PO28 | Long term effectiveness and safety of venous thromboembolism with fondaparinux: data from the start registry I.M. Palumbo¹, E. Valeriani^1,2, A. Pannunzio¹, S. Marucci³, D. Menichelli¹, D. Pastori^3,4, P. Pignatelli³ | ¹Department of General Surgery and Surgical Specialty, Sapienza University of Roma; ²Department of Infectious Disease, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Roma; ³Department of Clinical Internal, Anaesthesiologic and Cardiovascular Sciences, Sapienza University of Roma, Roma; ⁴IRCCS NeuRomad, Pozzilli, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.289

  481

  PDF: 0
• 

  PO11 | THROMBOEMBOLIC EVENTS DURING PERIOPERATIVE THERAPY FOR RESECTABLE AND BORDERLINE RESECTABLE PANCREATIC CANCER IN THE PREOPANC-2 TRIAL R.A.L. Willems^1|5, A.E. Van Diepen^1|2|6, EN. Dekker⁷, Q.P. Janssen⁷, J.L. Van Dam⁷, N. Michiels⁸, C.W.F. Van Eijck⁹, K.E.P.E. Hermans^1|2, B.A. Bonsing⁸, K.P. Bosscha¹⁰, S.A.W. Bouwense^11|12, O. R. Busch^13|14, H. Ten Cate^4|5|15|16, P.P.L.O. Coene¹⁷, C.H.J. Van Eijck⁷, N. Van Es^18|19, E. Van Der Harst¹⁷, I.H.J.T. De Hingh²⁰, T.M. Karsten²¹, G. Kazemier^13|14, M.B. Van Der Kolk²², B. De Laat^3|5, M.S.L. Liem²², J.S.D. Mieog⁸, V.B. Nieuwenhuijs²⁴, G.A. Patijn²⁴, M. Roest³, H.C. Van Santvoort²⁵, L. Valkenburg-Van Iersel^1|2, R. F. De Wilde⁷, F. Wit²⁶, B.M. Zonderhuis^13|14, M.G. Besselink^13|14, M.Y.V. Homs⁶, G. Van Tienhoven^14|27, J. W. Wilmink^14|28, B. Groot Koerkamp⁷, J. De Vos-Geelen^1|2 | ¹Maastricht University Medical Center, Department of Internal Medicine, Division of Medical Oncology; ²GROW – Research Institute for Oncology & Reproduction, Maastricht University, Maastricht; ³Synapse Research Institute, Department of Functional Coagulation, Maastricht; ⁴Maastricht University Medical Center, Thrombosis Expert Center Maastricht, Maastricht; ⁵Maastricht University Medical Center, Cardiovascular Research Institute Maastricht (CARIM), School for Cardiovascular Diseases, Maastricht; ⁶Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam; ⁷Erasmus MC Cancer Institute Rotterdam, University Medical Center Rotterdam, Department of Surgery; ⁸Leiden University Medical Center, Department of Surgery, Leiden; ⁹Solid Tumour Immunology Research Rotterdam (STIRR), Department of Pulmonary Medicine, Erasmus University Medical Centre, Rotterdam; ¹⁰Jeroen Bosch Hospital, Department of Surgery, Den Bosch; ¹¹Maastricht University Medical Center, Department of Surgery, Maastricht; ¹²Maastricht University Medical Center, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht; ¹³Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam; ¹⁴Cancer Center Amsterdam; ¹⁵Maastricht University Medical Center, Department of Internal Medicine, Division Vascular Medicine, Maastricht; ¹⁶Maastricht University, Department of Biochemistry, Laboratory for Clinical Thrombosis and Hemostasis, Maastricht; ¹⁷Maasstad Hospital, Department of Surgery, Rotterdam; ¹⁸Amsterdam UMC, location University of Amsterdam, Department of Vascular Medicine, Amsterdam; ¹⁹Amsterdam UMC, location University of Amsterdam, Amsterdam Cardiovascular Sciences, Pulmonary Hypertension & Thrombosis, Amsterdam; ²⁰Catharina Hospital, Department of Surgery, Eindhoven; ²¹OLVG, Department of Surgery, Amsterdam; ²²Radboud University Medical Center, Department of Surgery, Nijmegen; ²³Medisch Spectrum Twente, Department of Surgery, Enschede; ²⁴Isala Oncology Center, Department of Surgery, Zwolle; ²⁵Regional Academic Cancer Center Utrecht, St. Antonius Hospital and University Medical Center Utrecht, Department of Surgery, Utrecht; ²⁶Frisius MC, location Leeuwarden, Department of Surgery, Leeuwarden; ²⁷Amsterdam UMC, location University of Amsterdam, Department of Radiation Oncology, Amsterdam; ²⁸Amsterdam UMC, location University of Amsterdam, Department of Medical Oncology, Amsterdam, the Netherlands

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.507

  3

  PDF: 0
• 

  PO26 | OUTCOMES OF DIRECT ORAL ANTICOAGULANTS IN UNUSUAL-SITE THROMBOSIS: IMPACT OF ACTIVE CANCER S. Guglielmo¹, M. Lovisotto¹, L. Scarano¹, E. De Bon², S. Barbar² | ¹Internal Medicine, Department of Medicine, Azienda Ulss 6 Euganea, Cittadella (PD), Italy; ²Thrombotic and Hemorrhagic Disorders Unit, Department of Medicine, Azienda Ulss 6 Euganea, Cittadella (PD), Italy

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.521

  1

  PDF: 0
• 

  PO10 | RISK OF VENOUS THROMBOEMBOLISM IN CANCER PATIENTS WITH CENTRAL VENOUS CATHETERS: RESULTS FROM THE VIENNA CAT-BLED STUDY B. Sunder-Plassmann ¹, N, Vladic¹, C. Englisch¹, F. Moik^1|3, V. Sunder-Plassmann², A. Berghoff², M. Preusser², I. Pabinger¹, C. Ay¹ | ¹Division of Hematology and Haemostaseology, Department of Medicine I, Medical University of Vienna; Vienna, Austria; ²Division of Oncology, Department of Medicine I, Medical University of Vienna; Vienna, Austria; ³Division of Oncology, Department of Internal Medicine, Medical University of Graz; Graz, Austria

  Società Italiana di Emostasi e Trombosi

  16-04-2026

  https://doi.org/10.4081/btvb.2026.506

  1

  PDF: 0

• PO56 | Safety of anticoagulant treatment in patients with splanchnic vein thrombosis and history of portal hypertension-related bleeding R. Talerico¹, S. Pellegrino¹, A. Plessier², F.R. Ponziani³, A. Porfidia¹, F. Landi¹, A. Gasbarrini³, R. Pola¹, F. Santopaolo³ | ¹Department of Geriatric, Orthopedic, and Rheumatologic Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy; ²Université de Paris, AP-HP, C, DMU DIGEST, Centre de Référence des Maladies Vasculaires du Foie, FILFOIE, ERN RARE-LIVE. Centre de recherche sur l’inflammation, Inserm, Paris, France; ³Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy

  22-10-2025

  https://doi.org/10.4081/btvb.2025.325

  457

  PDF: 0